Stock Research for MNKD

MNKD

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MNKD Stock Chart & Research Data

The MNKD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNKD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MNKD Due diligence Resources & Stock Charts

The MNKD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MNKD Detailed Price Forecast - CNN Money CNN View MNKD Detailed Summary - Google Finance
Yahoo View MNKD Detailed Summary - Yahoo! Finance Zacks View MNKD Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View MNKD Trends & Analysis - Trade-Ideas Barrons View MNKD Major Holders - Barrons
NASDAQ View MNKD Call Transcripts - NASDAQ Seeking View MNKD Breaking News & Analysis - Seeking Alpha
Spotlight View MNKD Annual Report - CompanySpotlight.com OTC Report View MNKD OTC Short Report - OTCShortReport.com
TradeKing View MNKD Fundamentals - TradeKing Charts View MNKD SEC Filings - Bar Chart
WSJ View Historical Prices for MNKD - The WSJ Morningstar View Performance/Total Return for MNKD - Morningstar
MarketWatch View the Analyst Estimates for MNKD - MarketWatch CNBC View the Earnings History for MNKD - CNBC
StockMarketWatch View the MNKD Earnings - StockMarketWatch MacroAxis View MNKD Buy or Sell Recommendations - MacroAxis
Bullish View the MNKD Bullish Patterns - American Bulls Short Pains View MNKD Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View MNKD Stock Mentions - StockTwits PennyStocks View MNKD Stock Mentions - PennyStockTweets
Twitter View MNKD Stock Mentions - Twitter Invest Hub View MNKD Investment Forum News - Investor Hub
Yahoo View MNKD Stock Mentions - Yahoo! Message Board Seeking Alpha View MNKD Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for MNKD - SECform4.com Insider Cow View Insider Transactions for MNKD - Insider Cow
CNBC View MNKD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MNKD - OTC Markets
Yahoo View Insider Transactions for MNKD - Yahoo! Finance NASDAQ View Institutional Holdings for MNKD - NASDAQ


Stock Charts

FinViz View MNKD Stock Insight & Charts - FinViz.com StockCharts View MNKD Investment Charts - StockCharts.com
BarChart View MNKD Stock Overview & Charts - BarChart Trading View View MNKD User Generated Charts - Trading View




Latest Financial News for MNKD


Edited Transcript of MNKD earnings conference call or presentation 2-Aug-18 9:00pm GMT
Posted on Wednesday September 19, 2018

Q2 2018 MannKind Corp Earnings Call


Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics
Posted on Thursday September 13, 2018

WESTLAKE VILLAGE, Calif., Sept. 13, 2018-- MannKind Corporation announced today that "Improved Postprandial Glucose with Inhaled Technosphere ® Insulin Compared to Insulin Aspart in Patients with ...


Implied Volatility Surging for MannKind (MNKD) Stock Options
Posted on Monday September 10, 2018

MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.


Mannkind Afrezza Sales Have Doubled and Treprostinil is Getting Some Traction
Posted on Monday September 10, 2018

NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. On September 4th, MannKind announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. MNKD doubled its market share over the past year as a result of its commercialization efforts and are excited about its new Afrezza clinical data being released throughout 2018.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.